Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.12.19	Acquirer of SEK 121 million of convertible loan in Karolinska Development commits to set-off and the subscription period in the directed share issue is extended (GlobeNewswire)
11.12.19	Karolinska Development’s portfolio company Forendo Pharma enters license and collaboration agreement with leading pharma company (GlobeNewswire)
09.12.19	Karolinska Development´s portfolio company Aprea Therapeutics presents data from two Phase Ib/II studies of APR-246 at the American Society of Hematology meeting (GlobeNewswire)
29.11.19	Change of number of shares and votes in Karolinska Development (GlobeNewswire)
29.11.19	Interim Report January - September 2019 (GlobeNewswire)
20.11.19	Karolinska Development announces the result of the first partial registration in the directed share issue to the Company's convertible loan holders (GlobeNewswire)
07.11.19	Karolinska Development’s portfolio company OssDsign reports favourable outcome data on OSSDSIGN Cranial PSI (GlobeNewswire)
06.11.19	Karolinska Development publishes prospectus supplement relating to the directed share issue to the Company’s convertible holders (GlobeNewswire)
06.11.19	Holders of Karolinska Development’s convertible loan have agreed to set-off and repurchase 94 per cent of outstanding convertibles (GlobeNewswire)
05.11.19	New date for publication of Karolinska Developments Interim Report January – September 2019 (GlobeNewswire)
28.10.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
28.10.19	Karolinska Development divests its ownership in Asarina Pharma (GlobeNewswire)
14.10.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
14.10.19	Karolinska Development’s portfolio company OssDsign receives US FDA clearance for Cranial PSI Accessories (GlobeNewswire)
08.10.19	Karolinska Development’s portfolio company Aprea Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)
03.10.19	Karolinska Development’s portfolio company Aprea Therapeutics has priced its initial public offering (GlobeNewswire)
27.09.19	Karolinska Development publishes prospectus supplement relating to the directed share issue to the Company’s convertible holders (GlobeNewswire)
27.09.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
23.09.19	Karolinska Developments portfolio company Lipidor has been approved for listing on Nasdaq First North Growth Market (GlobeNewswire)
23.09.19	Karolinska Development’s portfolio company Aprea Therapeutics sets price range for potential initial public offering (GlobeNewswire)
12.09.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
09.09.19	Karolinska Development's portfolio company Aprea Therapeutics has filed a registration statement relating to its shares of common stock with the U.S. Securities and Exchange Commission (GlobeNewswire)
30.08.19	Interim Report January - June 2019 (GlobeNewswire)
29.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
28.08.19	Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant (GlobeNewswire)
20.08.19	Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219 (GlobeNewswire)
16.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
16.08.19	New date for publication of Karolinska Developments Interim Report January – June 2019 (GlobeNewswire)
09.08.19	arolinska Development's portfolio company OssDsign prepares for launch in Japan following regulatory filing (GlobeNewswire)
05.08.19	Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO (GlobeNewswire)
02.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
19.07.19	Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma (GlobeNewswire)
19.07.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
09.07.19	Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction (GlobeNewswire)
05.07.19	Karolinska Development publishes prospectus relating to the directed share issue (GlobeNewswire)
01.07.19	Karolinska Development appoints Fredrik Järrsten as Deputy CEO (GlobeNewswire)
28.06.19	Karolinska Development´s Annual General Meeting 2019 (GlobeNewswire)
28.06.19	Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan (GlobeNewswire)
27.06.19	Karolinska Development sells its ownership in Pharmanest for SEK 23 million (GlobeNewswire)
26.06.19	Announcement of the final terms and conditions of Karolinska Development’s directed share issue to the holders of the Company’s convertible loan (GlobeNewswire)
04.06.19	The Swedish Securities Council grants Sino Biopharmaceutical exemption from the mandatory bid obligation (GlobeNewswire)
29.05.19	Karolinska Development's Board of Directors proposes measures to resolve the company's convertible loan (GlobeNewswire)
29.05.19	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
28.05.19	Karolinska Development changes date for the Annual General Meeting (GlobeNewswire)
23.05.19	Karolinska Development’s portfolio company OssDsign reports substantial progress in the process towards reimbursement of OSSDSIGN PSI in France (GlobeNewswire)
21.05.19	Karolinska Development: Q1 2019 Interim Report – January-March (GlobeNewswire)
20.05.19	Karolinska Development’s portfolio company OssDsign’s share issue prior to listing on Nasdaq First North is oversubscribed (GlobeNewswire)
13.05.19	Karolinska Development's portfolio company Modus Therapeutics announces results from a Phase 2 study of sevuparin in patients with sickle cell disease (GlobeNewswire)
02.05.19	Karolinska Development’s portfolio company OssDsign applies for listing on Nasdaq First North (GlobeNewswire)
30.04.19	Karolinska Development publishes its Annual Report for 2018 with an update on the financial situation (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	262.10	3.39 %	K V
Lonza Grp	584.80	2.38 %	K V
Logitech Intl	66.76	1.71 %	K V
Part Grp Hldg	1’114.00	1.41 %	K V
Swisscom	544.00	0.74 %	K V
ABB	45.07	0.04 %	K V
Novartis	90.91	-0.22 %	K V
Zurich Insur Gr	581.00	-0.34 %	K V
Roche Hldg G	257.60	-0.88 %	K V
Kuehne+Nagel Int	177.85	-3.24 %	K V

Karolinska Development AB Aktie VALOR 3662575 / ISIN SE0002190926

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten